经过特殊血液过滤程序筛选后,患者的免疫细胞被送往实验室,之后医疗人员将细胞重新进行基因编码后,赋予其捕获癌细胞的能力。
These re-engineered T-cells are then transfused back into the patient, where they can begin attacking leukemia.
这些改造过的T细胞会被输回患者体内,对抗白血病。
Studies have shown that 83 percent of patients responded to the treatment, achieving remission within three months, Novartis said.
诺华称,研究发现,治疗对83%的患者有效,患者的病情在三个月内成功得到了缓解。
An application with the European Medicines Agency is expected to be filed by the end of the year.
诺华预计将于今年年底向欧洲药品管理局提出申请。
价格:每次47.5万美元
The price of Kymriah - which is delivered to a patient just once - is $475,000, said Bruno Strigini, CEO of Oncology at Novartis.
诺华肿瘤事业部CEO布鲁诺•斯蒂格尼说,Kymriah的价格是每次治疗47.5万美元。
Patients who do not respond to the treatment within the first month would not be expected to pay, he told reporters.
他对记者说,如果治疗一个月内对患者无效,那么患者无需付款。
The more common treatment for leukemia - bone marrow transplants - can cost between $540,000 and $800,000 the first year in the United States, Strigini said.
【首个白血病治疗基因疗法在美获批】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15